EGFR and non-small cell lung carcinoma: RTOG 0617 trial was a phase III study comparing a dose of 60 Gy versus 74 Gy delivered concurrently with weekly paclitaxel and carboplatin ± antibody against the epidermal growth factor receptor cetuximab in patients with locally advanced NSCLC.